2024
COVID-19 Vaccination in the First Trimester and Major Structural Birth Defects Among Live Births
Kharbanda E, DeSilva M, Lipkind H, Romitti P, Zhu J, Vesco K, Boyce T, Daley M, Fuller C, Getahun D, Jackson L, Williams J, Zerbo O, Weintraub E, Vazquez-Benitez G. COVID-19 Vaccination in the First Trimester and Major Structural Birth Defects Among Live Births. JAMA Pediatrics 2024, 178: 823-829. PMID: 38949821, PMCID: PMC11217887, DOI: 10.1001/jamapediatrics.2024.1917.Peer-Reviewed Original ResearchStructural birth defectsLive-born infantsFirst-trimesterBirth defectsCOVID-19 vaccineLive birthsRetrospective cohort study of singleton pregnanciesStudy of singleton pregnanciesVaccine exposureMessenger RNA COVID-19 vaccineMessenger RNAFirst-trimester vaccinationMRNA COVID-19 vaccinePrevent pregnancy complicationsRetrospective cohort studyStabilized inverse probability weightsElectronic health dataNeural tube defectsMedical record reviewMultisite cohort studyLMP dateVaccine Safety DatalinkCOVID-19 vaccine dosesSingleton pregnanciesEligible pregnanciesObstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination
Vesco K, Denoble A, Lipkind H, Kharbanda E, DeSilva M, Daley M, Getahun D, Zerbo O, Naleway A, Jackson L, Williams J, Boyce T, Fuller C, Weintraub E, Vazquez-Benitez G. Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination. Obstetrics And Gynecology 2024, 143: 794-802. PMID: 38626447, PMCID: PMC11090513, DOI: 10.1097/aog.0000000000005583.Peer-Reviewed Original ResearchConceptsSmall-for-gestational ageMessenger RNA COVID-19 vaccineGestational diabetes mellitusRisk of adverse pregnancy outcomesAdverse pregnancy outcomesPreterm birthGestational hypertensionAdjusted hazard ratiosCOVID-19 vaccine dosesPregnancy outcomesCOVID-19 vaccineAssociated with small-for-gestational ageIncreased risk of adverse pregnancy outcomesVaccine doseRisk of preterm birthMessenger RNARetrospective cohort study of individualsMRNA COVID-19 vaccineWeeks of gestationRetrospective cohort studyHistory of COVID-19Cohort study of individualsVaccine Safety DatalinkSingleton pregnanciesUnexposed pregnancies
2022
Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis
Stone CA, Robinson LB, Li L, Krantz MS, Kwah JH, Ortega G, Mancini C, Wolfson AR, Saff RR, Samarakoon U, Hong DI, Koo G, Chow TG, Gruchalla R, Liao JX, Kuster JK, Price C, Ahola C, Khan DA, Phillips EJ, Banerji A, Blumenthal KG. Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis. The Journal Of Allergy And Clinical Immunology In Practice 2022, 11: 458-465.e1. PMID: 36108922, PMCID: PMC9468049, DOI: 10.1016/j.jaip.2022.08.048.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineNovel clinical phenotypesCOVID-19 vaccineDose 1Second doseClinical phenotypeObjective signsLatent class analysisMRNA coronavirus disease 2019 (COVID-19) vaccinesDose toleranceAllergy/immunology specialistsMRNA COVID-19 vaccinationCoronavirus disease 2019 (COVID-19) vaccinesSelf-limiting symptomsFirst-dose reactionsU.S. academic medical centersLog-binomial regressionCOVID-19 vaccinationDistinct clinical phenotypesAcademic medical centerImmediate reactionsImmunology specialistsClass analysisAllergic symptomsRetrospective studyOperation Nasal Vaccine—Lightning speed to counter COVID-19
Topol EJ, Iwasaki A. Operation Nasal Vaccine—Lightning speed to counter COVID-19. Science Immunology 2022, 7: eadd9947. PMID: 35862488, DOI: 10.1126/sciimmunol.add9947.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineVaccine strategiesRespiratory mucosaRobust immunityCOVID-19MucosaVaccinePoor abilityImmunityImmunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDosesAntibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases
Harboe Z, Hamm S, Pérez-Alós L, Sivapalan P, Priemé H, Wilcke T, Kjeldgaard P, Shaker S, Jordan A, Møller D, Heftdal L, Madsen J, Bayarri-Olmos R, Hansen C, Pries-Heje M, Hasselbalch R, Fogh K, Armenteros J, Hilsted L, Sørensen E, Lindegaard B, Browatzki A, Biering-Sørensen T, Frikke-Schmidt R, Ostrowski S, Iversen K, Bundgaard H, Nielsen S, Garred P, Jensen J. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ Open Respiratory Research 2022, 9: e001268. PMID: 35793836, PMCID: PMC9260234, DOI: 10.1136/bmjresp-2022-001268.Peer-Reviewed Original ResearchConceptsChronic pulmonary diseaseCOVID-19 vaccinationPulmonary diseaseLow respondersRisk factorsHumoral responseBNT162b2 mRNA COVID-19 vaccineBNT162b2 COVID-19 vaccinationMRNA COVID-19 vaccineCharlson Comorbidity IndexProspective cohort studyUse of prednisolonePoor immunological responseFunctional humoral responseCOVID-19 vaccineAU/mLComorbidity indexCohort studyFirst vaccinationSecondary outcomesPrimary outcomeRBD IgGAntibody responseImmunological outcomesAntibody indexLongitudinal Study of DNA Methylation and Epigenetic Clocks Prior to and Following Test-Confirmed COVID-19 and mRNA Vaccination
Pang APS, Higgins-Chen AT, Comite F, Raica I, Arboleda C, Went H, Mendez T, Schotsaert M, Dwaraka V, Smith R, Levine ME, Ndhlovu LC, Corley MJ. Longitudinal Study of DNA Methylation and Epigenetic Clocks Prior to and Following Test-Confirmed COVID-19 and mRNA Vaccination. Frontiers In Genetics 2022, 13: 819749. PMID: 35719387, PMCID: PMC9203887, DOI: 10.3389/fgene.2022.819749.Peer-Reviewed Original ResearchSevere COVID-19T cellsCOVID-19 diagnosisMRNA vaccinationCOVID-19B cellsCOVID-19 vaccine responsesNon-hospitalized COVID-19MRNA COVID-19 vaccineSARS-CoV-2 infectionHost epigenetic landscapeMedian time frameExhausted T cellsNaïve T cellsCOVID-19 vaccinationCOVID-19 exposureCOVID-19 vaccineEpigenetic clock analysisModerna mRNAVaccine responsesImmune cellsEpigenetic clocksHealthy individualsVaccinationLongitudinal assessmentImmunogenicity and Antibody Titers After BNT162b2 mRNA COVID-19 Vaccine, Breakthrough Infection and Booster
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. Immunogenicity and Antibody Titers After BNT162b2 mRNA COVID-19 Vaccine, Breakthrough Infection and Booster. 2022, a3130-a3130. DOI: 10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3130.Peer-Reviewed Original ResearchBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 vaccineBreakthrough infectionsAntibody titers
2021
Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine
Woo W, Kim A, Yon D, Lee S, Hwang J, Jacob L, Koyanagi A, Kim M, Moon D, Jung J, Choi J, Jung S, Eun L, Lee S, Shin J, Smith L. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine. Journal Of Medical Virology 2021, 94: 1566-1580. PMID: 34862617, PMCID: PMC9015469, DOI: 10.1002/jmv.27501.Peer-Reviewed Original ResearchConceptsGastrointestinal symptomsMRNA-1273Conservative careIntensive careAnalyzed clinical manifestationsMRNA COVID-19 vaccineLeft ventricular dysfunctionProportion of patientsMRNA-1273 vaccineOutcome of myocarditisIntensive care unitInvestigate risk factorsMagnetic resonance imagingRisk factor analysisMRNA-1273 recipientsPrognostic factorsVentricular dysfunctionClinical courseEjection fractionMedian ageClinical presentationMyocardial inflammationCase seriesClinical characteristicsCase reportCOVID-19 vaccine – Long term immune decline and breakthrough infections
Khoury J, Najjar-Debbiny R, Hanna A, Jabbour A, Abu Ahmad Y, Saffuri A, Abu-Sinni M, Shkeiri R, Elemy A, Hakim F. COVID-19 vaccine – Long term immune decline and breakthrough infections. Vaccine 2021, 39: 6984-6989. PMID: 34763949, PMCID: PMC8556595, DOI: 10.1016/j.vaccine.2021.10.038.Peer-Reviewed Original ResearchConceptsAntibody titersCOVID-19 vaccineBreakthrough infectionsSecond doseAntibody levelsPolymerase chain reactionBNT162b2 mRNA COVID-19 vaccineSARS-CoV-2 polymerase chain reactionMRNA COVID-19 vaccineStudy periodBreakthrough infection rateMedian antibody levelsMean antibody levelsLongitudinal prospective studyAntibody declineTiter elevationImmune declineProspective studyClinical indicationsMild casesHealthcare personnelInfection rateInfectionVaccinePeak levelsEffectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
Nanduri S, Pilishvili T, Derado G, Soe M, Dollard P, Wu H, Li Q, Bagchi S, Dubendris H, Link-Gelles R, Jernigan J, Budnitz D, Bell J, Benin A, Shang N, Edwards J, Verani J, Schrag S. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 1163-1166. PMID: 34437519, PMCID: PMC8389386, DOI: 10.15585/mmwr.mm7034e3.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkSARS-CoV-2 infectionNursing home residentsLong-term care facility residentsMRNA COVID-19 vaccineCOVID-19 vaccineVaccine effectivenessCare facility residentsHome residentsDelta variantPfizer-BioNTechModerna vaccineMRNA vaccinesFacility residentsNursing homesCDC's National Healthcare Safety NetworkPreventing SARS-CoV-2 InfectionSevere COVID-19-associated outcomesVaccine-induced immunityNursing home staff membersProtective immune responseCOVID-19 prevention strategiesWeekly reportsEmergency use authorizationSkilled nursing facilitiesAmerican Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ, Group F. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021, 74: 1049-1064. PMID: 33577086, PMCID: PMC8014184, DOI: 10.1002/hep.31751.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineChronic liver diseaseLiver diseaseModerna mRNA COVID-19 vaccinesCoronavirus disease 2019 (COVID-19) infectionExpert panel consensus statementPrevious drug reactionsAdvanced liver diseaseLiver transplant recipientsAvailable COVID-19 vaccinesDisease 2019 infectionSevere hypersensitivity reactionsLocal site reactionsCare of patientsClinical trial participantsHealth care providersLT recipientsTransplant recipientsAdult patientsImmunosuppressed patientsSystemic reactionsHypersensitivity reactionsSite reactionsVaccine efficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply